Axsome to Double Sales Team after $155M AUVELITY Quarter, $600M Run Rate
Axsome reported AUVELITY sales of $155 million this quarter, driving an annualized run rate above $600 million 13 quarters after launch with just 0.2% market penetration. The company will double its field force from 300 to 600 reps ahead of the April 30 PDUFA date for AXS-05 Alzheimer’s agitation.
1. AUVELITY Sales Performance
AUVELITY generated $155 million in quarterly revenue and is annualizing north of $600 million just 13 quarters after launch. Despite this rapid growth, the product’s current footprint remains approximately 0.2% of the total antidepressant market, underscoring significant upside potential.
2. Salesforce Expansion Strategy
Management plans to expand its field force from 300 to 600 representatives, leveraging prior ROI analyses and learnings from past expansions. The enlarged team will support both depression prescriptions and a potential Alzheimer’s agitation indication, targeting overlap in prescriber profiles.
3. Financial and Operating Leverage
In 2025, Axsome achieved operating leverage with revenues outpacing operating expense growth by a 3-to-1 ratio. SG&A increased from about $150 million in Q3 to nearly $170 million in Q4 due to DTC advertising campaigns, with 2026 spending forecast between those levels.
4. Alzheimer’s Agitation sNDA Progress
The supplemental NDA for AXS-05 in Alzheimer’s disease agitation is under priority review, with a PDUFA date of April 30. The submission includes long-term safety data from roughly 100 patients at 12 months and 300 patients at six months, positioning it for potential approval.